Proposed UK rules on plain packaging and tighter vape branding have pushed tobacco harm reduction into the spotlight, and some stocks are more exposed to this debate than others. For investors tracking how regulation shapes risk and opportunity, this screener focuses on companies tied to reduced risk nicotine products and cessation tools. In this article, you will see 3 stocks that appear positively exposed to the latest UK consultation around vaping and tobacco, and how their business focus might interact with tougher rules on flavours, packaging and marketing. The goal is to help you decide where this theme fits in your portfolio.

Perrigo (PRGO)

Overview: Perrigo is a Dublin based consumer health company that sells over the counter products such as cough and cold remedies, infant formula, pain relief, oral care and vitamins, along with smoking cessation and other self care items, largely under store brand and well known consumer labels. Its products sit on pharmacy, supermarket and e commerce shelves across the US, Europe and other international markets.

Operations: Perrigo generates about US$4.2b in revenue, with roughly US$2.5b from the United States and about US$1.6b from Europe excluding Ireland, alongside smaller contributions from Ireland and other countries.

Market Cap: US$1.5b

Perrigo stands out in the UK vaping debate because it already focuses on regulated nicotine replacement therapies and over the counter smoking cessation aids rather than flavoured vapes that could face tighter rules. The company is working through leadership changes, recent losses and a goodwill impairment, yet analysts highlight its large store brand OTC and infant nutrition platform as a key asset. At the same time, a high dividend that is not well covered, legal disputes and slow projected revenue growth mean you need to weigh income and value appeal against execution and balance sheet risks, including the potential impact of any changes in tobacco and vape regulation.

Perrigo’s large store brand platform could be masking a very different risk and reward balance than the headline dividend suggests, so it is worth studying the 4 key rewards and 1 important major warning sign

Rubicon Organics (TSXV:ROMJ)

Overview: Rubicon Organics is a Vancouver based cannabis company that produces and sells organic recreational and medical cannabis, offering dried flower, pre rolls, vapes, concentrates, edibles, topicals and oils under brands such as Simply Bare Organic, 1964 Supply Co, Homestead Cannabis Supply and Wildflower in Canada and select international markets.

Operations: Rubicon Organics generates about CA$60.8m in revenue from the production and sale of cannabis, with all of this currently coming from Canada.

Market Cap: CA$29.7m

Rubicon Organics sits at the crossroads of premium cannabis and tighter nicotine and vape scrutiny, with its 1964 Supply Co vapes and UK partnership giving it a foothold in regulated medical channels just as authorities talk about plainer packaging and stricter marketing. The company has shown it can grow revenue, but continues to report losses, has less than one year of cash runway and relies on external borrowing, so funding and execution risks are front of mind. For investors, the appeal lies in its organic, wellness focused brands, expanding product range and international routes to market, set against a small market cap, heavy Canadian exposure and an industry where regulation and pricing can quickly reshape expectations.

Rubicon Organics sits at the intersection of wellness branding and funding pressure, and the real story is how that tension could resolve next, so it is worth reading the 3 key rewards and 1 important warning sign

Organigram Global (TSX:OGI)

Overview: Organigram Global is a Toronto headquartered cannabis producer that sells medical and adult use products, including flower, pre rolls, vapes, beverages, gummies and concentrates, across Canada and select international markets under brands such as SHRED, Edison Cannabis Co., Boxhot and Monjour. It also wholesales cannabis cuttings and dried flower to other licensed producers and distributes through retail, wholesale and online channels in both recreational and medical regimes.

Operations: Organigram Global generates about CA$274.2m from the production and sale of cannabis, with reported revenue primarily linked to Canada and smaller contributions from international markets.

Market Cap: CA$196.4m

Organigram Global operates at the intersection of harm reduction and cannabis liberalisation, which is why the UK’s push toward plainer vape packaging may be relevant for investors. The company is building out international medical routes into markets such as Germany and the UK, using a mix of partners like Sanity Group and direct distribution. It has also raised its revenue guidance for fiscal 2026 after acquiring Sanity Group. At the same time, it remains unprofitable, reported recent impairments and has taken on new term loans and revolving credit facilities, so funding and execution risks are present. This combination of growth plans, balance sheet pressure and regulatory shifts could influence the risk reward profile for Organigram over time.

Organigram Global’s expanding medical footprint and new partnerships hint at a story that many investors may be only half seeing, so it is worth reading the analyst forecasts for Organigram Global to understand what could be driving the next chapter.

The three stocks here are only a starting point, and the full Tobacco Harm Reduction Companies screener on Simply Wall St surfaces 5 more companies with equally compelling stories that could matter for your portfolio thesis, so it is worth reviewing the Tobacco Harm Reduction Companies screener. Use Simply Wall St to identify, filter and analyze the specific catalysts and narratives around nicotine replacement, smoking cessation and non combustible products so you can focus on the highest conviction opportunities within this theme.

Take Control of Your Investment Journey

If Organigram Global or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Momentum Flies Past?

Fresh stock ideas can move from under the radar to fully priced as soon as momentum catches on. Consider these focused lists before the crowd and decide whether they fit your strategy.

• Spot robust businesses that could hold up when others are dropping by working through a curated 73 resilient stocks with low risk scores that is built to keep risk front and center.
• Explore potential upside where AI cash flows already matter, not just the story, by scanning the hand picked 63 profitable AI stocks that aren't just burning cash that filters for real earnings support.
• Review potential infrastructure themes by using the targeted 34 power grid technology and infrastructure stocks highlighting companies tied to critical grid upgrades while it matters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.